omniture
PHARMABCINE INC

Latest News

PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration

* Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC...

2024-10-15 09:51 1182

PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg

* Safety Review Committee (SRC) approves single 3mg dose for the third cohort in Phase 1 trial of...

2024-07-02 11:02 2139

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024

* Presentation at ARVO 2024 gained attention as Eylea (aflibercept) eye drops demonstrated simila...

2024-05-23 08:51 1557

PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors

* Initiation of Phase 1a/b clinical trial exploring MTD, RP2D, safety and tolerability of PMC-309...

2024-01-24 10:01 1290

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

* Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (IS...

2023-11-23 10:31 1613

PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

DAEJEON, South Korea, July 26, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical...

2023-07-26 20:00 1645

PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

DAEJEON, South Korea, May 23, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-...

2023-05-23 20:00 1743

PharmAbcine to participate in "BIO International Convention 2023"

DAEJEON, South Korea, May 8, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-s...

2023-05-08 20:00 2113

PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)

DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical...

2022-12-12 21:00 1898

PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week

DAEJEON, South Korea, Dec. 8, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-...

2022-12-08 21:00 1692

PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

DAEJEON, South Korea, Oct. 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical...

2022-10-17 20:00 1167

PharmAbcine to Participate in BIO-Europe 2022

DAEJEON, South Korea, Sept. 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinica...

2022-09-26 20:00 1353

PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention

DAEJEON, South Korea, May 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-...

2022-05-11 20:00 2216

PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study

DAEJEON, South Korea, April 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinica...

2022-04-26 20:30 1420

PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

DAEJEON, South Korea, April 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinica...

2022-04-26 20:00 1437

PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022

DAEJEON, South Korea, April 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), aclinical...

2022-04-11 20:00 733

RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics

SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- RNAGene Inc., a South Korean biotech which speci...

2022-03-21 20:00 1687

NuclixBio Announces a Collaborative Research Agreement with PharmAbcine

SEOUL, South Korea, March 14, 2022 /PRNewswire/ -- NuclixBio Inc., a South Korean biotech company t...

2022-03-14 20:00 1916
123